Pharmaceuticals - Generics, Specialty, Biosimilars, and Consumer Healthcare
Strategic Profile
Cipla is the 3rd largest player in the private Rx market in South Asia and the fastest growing generic player in North America. The company holds leadership positions in respiratory care and top-5 rankings in urology and anti-infectives in the domestic market.
Cyborg Score Rationale
Cipla is almost debt-free and has delivered strong profit growth of 28.7% CAGR over the past 5 years with healthy dividend payouts. However, recent earnings misses and margin pressure offset strong market positions.
Top Insights
CEO transition underway: MD Umang Vohra will not seek reappointment; Global COO Achin Gupta takes over as CEO on April 1, 2026.
GST inspection concluded in Maharashtra on February 7-8, 2026; no material impact reported.
Arun Kakatkar appointed Global Chief People Officer effective March 17, 2026.
Q3 results missed expectations with EPS surprise of -27.14% and net income down 50% QoQ despite revenue of 70.75B INR.
Named Competitors
Dr. Reddy's Laboratories — Integrated pharma with strong generic and API presence
Sun Pharmaceutical — Large diversified pharma with specialty and generic focus
Lupin Limited — Global pharma company with respiratory and cardiac expertise
Aurobindo Pharma — Generics-focused pharma with US and emerging market presence
Recent Developments
(February 2026) GST inspection at Maharashtra facilities concluded with no material impact
(February 2026) Arun Kakatkar appointed Global Chief People Officer
(January 2026) MD Umang Vohra to step down; Achin Gupta assumes CEO role on April 1, 2026
Open the full interactive Cipla Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.